COVID-19: New Vaccine Shows Promising Results - Researchers |READ FULL
Afnews Editor
Jul 15, 2020
A COVID-19 vaccine developed by the biotechnology company, Morderna, has shown promise in key early trial, producing immune responses in all persons it was tested on.
The study, which involved 45 healthy adults aged 18-55 years, showed that the vaccine worked to trigger an immune responses in all the participants.
READ ALSO: AMAZlNG: Nollywood Actress Omotola & Her 1st Son [PHOTOS]
The study, published in the New England Journal of Medicine on Tuesday, was co-developed by researchers at the National Institute of Allergy and Infectious Diseases.
READ ALSO: Afrique Styles & Concepts Inducted Into UN's International Parliament For Safety, Peace & Justice
The researchers evaluated two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 ╬╝g, 100 ╬╝g, or 250 ╬╝g and the initial results from participants showed that the antibody responses among participants were higher with higher dose.
READ ALSO: Jim Iyke Sparks Outrage: "Doctors Are Trained Not to Heal - Sickness Is Their BusinessÔÇØ
However, the study showed that participants experienced mild side effects such as fatigue, chills, headache, myalgia (muscle pain or muscle ache) xx aand pain at the injection location.
READ ALSO: How a Nigerian Professor's AI System Could Predict Depression Before Symptoms Emerge
The researchers, led by Lisa Jackson, noted that "the mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.ÔÇØ
On the safety of the vaccine, they said "no serious adverse events were noted, and no pre-specified trial halting rules were met.ÔÇØ
They added that "local adverse events, when present, were nearly all mild or moderate, and pain at the injection site was common.
READ ALSO: You Are Wonderful And Amazing - Laycon Sends A Message To Erica (Video)
"Across both vaccinations, solicited systemic and local adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site.ÔÇØ
READ ALSO: REVEALED: How Common House Rats Can Kill - Shocking Truth Behind Silent Deaths in Nigerian Homes
The researchers said the safety and immunogenicity findings support advancement of the mRNA-1273 vaccine to later-stage clinical trials.
"Of the three doses evaluated, the 100-╬╝g dose elicits high neutralization responses and Th1-skewed CD4 T cell responses, coupled with a reactogenicity profile that is more favourable than that of the higher dose.
READ ALSO: Why Military Seized Power In Gabon
"A phase 2 trial of mRNA-1273 in 600 healthy adults, evaluating doses of 50 ╬╝g and 100 ╬╝g, is ongoing.
READ ALSO: VIDEO/PHOTOS: Fani-Kayode Kneels Down For Prayers To Become President Of Nigeria
"A large phase 3 efficacy trial, expected to evaluate a 100-╬╝g dose, is anticipated to begin during the summer of 2020,ÔÇØ they explained.
Related Stories
How Nonchalant Attitude at Federal Medical Centre Umuahia Is Turning Accident Victims Into Casualties - Shocking Findings Emerge
How a Nigerian Professor's AI System Could Predict Depression Before Symptoms Emerge
Jim Iyke Sparks Outrage: "Doctors Are Trained Not to Heal - Sickness Is Their BusinessÔÇØ
Why Nigeria Must Declare a State of Emergency on Malaria - Hon. Amobi Ogah Reveals at National Retreat
'Buhari Died In London Hospital After Promising Nigerians Quality Healthcare' - Activist Adetoun Attacks Late Ex President
REVEALED: How Common House Rats Can Kill - Shocking Truth Behind Silent Deaths in Nigerian Homes
""
— Afnews Editor